Circulating Mesenchymal Stem Cells, Stromal Derived Factor (Sdf)-1 and Ip-10 Levels Increased in Clinically Active Multiple Sclerosis Patients But Not in Clinically Stable Patients Treated With Beta Interferon Publisher Pubmed



Emamnejad R^{1, 4} ; Sahraian M² ; Shakiba Y³ ; Salehi Z⁴ ; Masoomi A⁵ ; Imani D⁴ ; Najafi F⁴ ; Laribi B⁴ ; Shirzad H¹ ; Izad M^{2, 4} Show Affiliations
Source: Multiple Sclerosis and Related Disorders Published:2019

Abstract

Background: Mesenchymal stem cells (MSCs) have the capacity to migrate into the inflammatory regions in response to chemokines such as, IP-10 and SDF-1α and function as anti-inflammatory and immunomodulatory cells. Methods: In this study we investigated the MSCs frequency in peripheral blood of Relapsing-Remitting Multiple Sclerosis (RRMS) patients in clinically active and not on disease-modifying therapy (DMT) (n = 22) and clinically stable on DMT (Interferon-β (IFN-β) therapy) for at least 6 months (n = 22) in comparison to sex and age-matched healthy controls (n = 25) using flow cytometry. The serum and gene expression levels of IP-10 and SDF-1a were also measured in studied groups by ELISA and Real time- PCR. Results: We obtained significant high levels of circulating CD45−CD34− CD90+ and CD45−CD34− CD105+ cells in clinically active patients, not on DMT and patients under IFNβ therapy compared with control group. Furthermore, a significant increase in the percentage of circulating CD45−CD34− CD105+ CD90+ cells was found in clinically active patients and not on DMT compared with control group. Serum analysis of IP-10 and SDF-1α showed a significant increase in IP10 concentration in both clinically active not on DMT (P = 0.02) and on DMT (P = 0.005) RRMS patients in comparison with controls. The expression level of SDF-1α mRNA significantly increased in clinically active not on DMT (P = 0.03), while decreased in patients under IFNβ therapy (P = 0.04). The mRNA expression of IP-10 only increased in patients on DMT compared with controls (P = 0.05). Conclusion: Circulating MSCs, IP-10 and SDF-1α levels, increased in RRMS patients with clinically active not on DMT and IFN-β therapy reduced circulating MSCs and SDF-1α levels. © 2019